EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Loss‐of‐function genetic screen unveils synergistic efficacy of PARG inhibition with combined 5‐fluorouracil and irinotecan treatment in colorectal cancer

Cristina Queralt iD, Cristina Moreta-Moraleda iD, Marta Costa iD, Ferran Grau-Leal iD, Jeannine Diesch iD, Carla Vendrell-Ayats iD, Eva Musulén iD, Roni H G Wright iD, Cristina Bugés iD, José Luis Manzano iD, Sara Cabrero-de Las Heras iD, Johannes Zuber iD und 3 weitere

Clinical and Translational Medicine · 2025

DOI: 10.1002/ctm2.70543 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2025. Verfasst von Cristina Queralt und 14 weiteren Autor:innen. Beteiligte Einrichtung: CARE Program, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain. Hauptthemen laut MEDLINE: Irinotecan, Fluorouracil, Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya, MICIU/AEI/10.13039/501100011033/FEDER, UE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Colorectal cancer (CRC) remains a major global health concern, partly due to resistance to therapy and the lack of new effective treatments for advanced disease. The combination of 5‐Fluorouracil (5FU, a thymidylate synthase inhibitor) and irinotecan (a topoisomerase 1 inhibitor) is widely used in first‐line and subsequent treatments. This study aimed to identify novel therapeutic targets to enhance combinatorial therapy, improving treatment efficacy and durability of response.

Methods

We performed a loss‐of‐function screen using HT29 CRC cell line and a retroviral library containing 7296 shRNAs targeting 912 chromatin genes. Cells were then treated with 5FU and SN38 (the active metabolite of irinotecan) or left untreated for 4 weeks. Genes enriched in resistant clones were identified through next‐generation sequencing. Amongst candidate genes, PARG was selected for functional validation.

Results

CRISPR/Cas9‐mediated knockout (HT29 PARG‐KO) resulted in increased global poly(ADP‐ribosyl)ation after 5FU and SN38 treatment. PARG depletion led to reduced cell viability and increased apoptosis, particularly after 5FU exposure. Pharmacological PARG inhibition (PDD00017273) synergised with 5FU and SN38 across three CRC models (HT29, DLD1, HT115). In vivo, HT29 PARG‐KO xenografts were more sensitive to 5FU. Immunohistochemical analysis of 170 CRC patient tumours revealed that positive PARG expression correlated with poor response to 5FU + Irinotecan, increased liver metastases, and worse long‐term survival.

Conclusions

Our findings highlight PARG as a promising therapeutic target for CRC, where its inhibition enhances the efficacy of standard chemotherapy. Key points LOF screening identified PARG as a modulator of CRC response to FUIRI treatment. HT29 PARG‐KO cells showed increased PAR, DNA damage, apoptosis, and 5FU sensitivity. Pharmacological PARG inhibition synergised with 5FU and SN38 in CRC cell lines. HT29 PARG‐KO tumours exhibited increased sensitivity to 5FU treatment in vivo. PARG expression in CRC tumours correlated with poorer responses and patient survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IrinotecanFluorouracilColorectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansAnimalsMiceDrug SynergismHT29 CellsCell Line, TumorXenograft Model Antitumor Assays

Stichwörter der Autor:innen

5FUFUIRIPARGPDD00017273colorectal canceririnotecanloss‐of‐function screening

Substanzen

IrinotecanFluorouracil

Autor:innen und Institutionen

  • CARE Program, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
  • ProCURE Program, Institut Català d'Oncologia, Badalona, Spain.
  • Badalona Applied Research Group of Oncology (B-ARGO), Medical Oncology Department, Institut Català d'Oncologia, Badalona, Spain.
  • Cancer and Leukaemia Epigenetics and Biology Program, Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-IGTP-UAB, Badalona, Spain.
  • Hospital Universitari General de Catalunya-Grupo Quironsalud, Sant Cugat del Vallès, Spain.
  • Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-IGTP-UAB, Badalona, Spain.

ORCID-Profile: Cristina Queralt, Cristina Moreta-Moraleda, Marta Costa, Ferran Grau-Leal, Jeannine Diesch, Carla Vendrell-Ayats, Eva Musulén, Roni H G Wright, Cristina Bugés, José Luis Manzano, Sara Cabrero-de Las Heras, Johannes Zuber, Marcus Buschbeck, Sonia-V Forcales, Eva Martínez-Balibrea

Förderung

  • Instituto de Salud Carlos III
  • Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya
  • MICIU/AEI/10.13039/501100011033/FEDER, UE
  • Fundación Olga Torres
  • HORIZON EUROPE Marie Sklodowska-Curie Actions
  • 'la Caixa' Foundation
  • LES BATES BLANQUES
  • Fundación Científica Asociación Española Contra el Cáncer

Zitieren

APA

Queralt, C., Moreta-Moraleda, C., Costa, M., Grau-Leal, F., Diesch, J., Vendrell-Ayats, C., Musulén, E., Wright, R. H. G., Bugés, C., Manzano, J. L., Cabrero-de Las Heras, S., Zuber, J., Buschbeck, M., Forcales, S. V., & Martínez-Balibrea, E. (2025). Loss‐of‐function genetic screen unveils synergistic efficacy of PARG inhibition with combined 5‐fluorouracil and irinotecan treatment in colorectal cancer. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70543

Vancouver

Queralt C, Moreta-Moraleda C, Costa M, Grau-Leal F, Diesch J, Vendrell-Ayats C, et al. Loss‐of‐function genetic screen unveils synergistic efficacy of PARG inhibition with combined 5‐fluorouracil and irinotecan treatment in colorectal cancer. Clinical and Translational Medicine. 2025. doi:10.1002/ctm2.70543

BibTeX
@article{Queralt2025,
  author = {Queralt, Cristina and Moreta-Moraleda, Cristina and Costa, Marta and Grau-Leal, Ferran and Diesch, Jeannine and Vendrell-Ayats, Carla and Musulén, Eva and Wright, Roni H G and Bugés, Cristina and Manzano, José Luis and Cabrero-de Las Heras, Sara and Zuber, Johannes and Buschbeck, Marcus and Forcales, Sonia-V and Martínez-Balibrea, Eva},
  title = {Loss‐of‐function genetic screen unveils synergistic efficacy of PARG inhibition with combined 5‐fluorouracil and irinotecan treatment in colorectal cancer},
  journal = {Clinical and Translational Medicine},
  year = {2025},
  doi = {10.1002/ctm2.70543}
}
Kostenlos starten →